Drug Profile
Interferon alpha-2b inhalation - Aradigm
Alternative Names: Inhaled interferon alfa-2b - AradigmLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Aradigm Corporation
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Hepatitis C
Most Recent Events
- 22 Mar 2007 Discontinued - Phase-I for Cancer in USA (Inhalation)
- 22 Mar 2007 Discontinued - Phase-I for Hepatitis C treatment in USA (Inhalation)
- 23 Jul 2002 Phase-I clinical trials in Cancer in USA (Inhalation)